WebJul 20, 2024 · Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of... WebOct 14, 2024 · Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer (mCRC). 1. The company ...
Celyad Oncology Presents Updates on shRNA-Based CAR T
WebDec 13, 2024 · Celyad Oncology will host a conference call to discuss the update from ASH on Monday, December 13, 2024 at 2:30 p.m. CET / 8:30 a.m. EST. The conference call can be accessed through the following ... WebAug 5, 2024 · Celyad Oncology SA: ClinicalTrials.gov Identifier: NCT04991948 Other Study ID Numbers: CYAD-101-002 KEYNOTE-B79 ( Other Identifier: Celyad Oncology ) First Posted: August 5, 2024 Key Record Dates: Last Update Posted: March 9, 2024 Last Verified: February 2024 Individual Participant Data (IPD) Sharing Statement: ... giddy goose christmas menu
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With ...
WebMar 23, 2024 · MONT-SAINT-GUIBERT, Belgium, March 23, 2024 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2024 ended December … WebNov 3, 2024 · Celyad Oncology SA: ClinicalTrials.gov Identifier: NCT04613557 Other Study ID Numbers: CYAD-211-001 : First Posted: November 3, 2024 Key Record Dates: Last Update Posted: November 30, 2024 Last Verified: November 2024 Layout table for additional information; Studies a U.S. FDA-regulated Drug Product: ... WebCelyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen … fruit heart cake